Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25

Debbie L. Hay, Michael L. Garelja, David R Poyner, Christopher S. Walker

Research output: Contribution to journalArticle

Abstract

The calcitonin/calcitonin gene-related peptide (CGRP) family of peptides includes calcitonin, α and β CGRP, amylin, adrenomedullin (AM) and adrenomedullin 2/intermedin (AM2/IMD). Their receptors consist of one of two G protein-coupled receptors (GPCRs), the calcitonin receptor (CTR) or the calcitonin receptor-like receptor (CLR). Further diversity arises from heterodimerisation of these GPCRs with one of three receptor activity-modifying proteins (RAMPs). This gives the CGRP receptor (CLR/RAMP1), the AM1 and AM2 receptors (CLR/RAMP2 or RAMP3) and the AMY1, AMY2 and AMY3 receptors (CTR/RAMPs1-3 complexes, respectively). Apart from the CGRP receptor, there are only peptide antagonists widely available for these receptors and these have limited selectivity, thus defining the function of each receptor in vivo remains challenging. Further challenges arise from the probable co-expression of CTR with the CTR/RAMP complexes and species-dependent splice variants of the CTR (CT(a) and CT(b)). Furthermore, the AMY1(a) receptor is activated equally well by both amylin and CGRP and the preferred receptor for AM2/IMD has been unclear. However, there are clear therapeutic rationales for developing agents against the various receptors for these peptides. For example many agents targeting the CGRP system are in clinical trials and pramlintide, an amylin analogue, is an approved therapy for insulin-requiring diabetes. This review provides an update on the pharmacology of the calcitonin family of peptides by members of the corresponding subcommittee of the International Union of Basic and Clinical Pharmacology and colleagues.
LanguageEnglish
Number of pages41
JournalBritish Journal of Pharmacology
VolumeIn press
Early online date23 Oct 2017
DOIs
Publication statusPublished - 28 Nov 2017

Fingerprint

Calcitonin Receptors
Calcitonin Gene-Related Peptide
Calcitonin
Calcitonin Receptor-Like Protein
Calcitonin Gene-Related Peptide Receptors
Islet Amyloid Polypeptide
Adrenomedullin
Pharmacology
Receptor Activity-Modifying Proteins
Peptides
G-Protein-Coupled Receptors
Peptide Receptors
Clinical Pharmacology
Clinical Trials
Insulin
Therapeutics

Bibliographical note

© 2017 The British Pharmacological Society and John Wiley & Sons, Inc. This is the peer reviewed version of the following article, which has been published in final form at http://onlinelibrary.wiley.com/doi/10.1111/bph.14075/abstract. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

Funder: Biotechnology and Biological Sciences Research Council (GrantNumber(s): BB/M000176/1).
Running title: Pharmacology of the calcitonin/CGRP family appears under main title in pdf format.

Keywords

  • Adrenomedullin
  • amylin
  • calcitonin
  • CGRP
  • migraine
  • diabetes

Cite this

Hay, Debbie L. ; Garelja, Michael L. ; Poyner, David R ; Walker, Christopher S. / Update on the pharmacology of calcitonin/CGRP family of peptides : IUPHAR Review 25. In: British Journal of Pharmacology. 2017 ; Vol. In press.
@article{b9cd81d6ddc04453849632bdbb0ecfe9,
title = "Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25",
abstract = "The calcitonin/calcitonin gene-related peptide (CGRP) family of peptides includes calcitonin, α and β CGRP, amylin, adrenomedullin (AM) and adrenomedullin 2/intermedin (AM2/IMD). Their receptors consist of one of two G protein-coupled receptors (GPCRs), the calcitonin receptor (CTR) or the calcitonin receptor-like receptor (CLR). Further diversity arises from heterodimerisation of these GPCRs with one of three receptor activity-modifying proteins (RAMPs). This gives the CGRP receptor (CLR/RAMP1), the AM1 and AM2 receptors (CLR/RAMP2 or RAMP3) and the AMY1, AMY2 and AMY3 receptors (CTR/RAMPs1-3 complexes, respectively). Apart from the CGRP receptor, there are only peptide antagonists widely available for these receptors and these have limited selectivity, thus defining the function of each receptor in vivo remains challenging. Further challenges arise from the probable co-expression of CTR with the CTR/RAMP complexes and species-dependent splice variants of the CTR (CT(a) and CT(b)). Furthermore, the AMY1(a) receptor is activated equally well by both amylin and CGRP and the preferred receptor for AM2/IMD has been unclear. However, there are clear therapeutic rationales for developing agents against the various receptors for these peptides. For example many agents targeting the CGRP system are in clinical trials and pramlintide, an amylin analogue, is an approved therapy for insulin-requiring diabetes. This review provides an update on the pharmacology of the calcitonin family of peptides by members of the corresponding subcommittee of the International Union of Basic and Clinical Pharmacology and colleagues.",
keywords = "Adrenomedullin , amylin , calcitonin , CGRP , migraine , diabetes",
author = "Hay, {Debbie L.} and Garelja, {Michael L.} and Poyner, {David R} and Walker, {Christopher S.}",
note = "{\circledC} 2017 The British Pharmacological Society and John Wiley & Sons, Inc. This is the peer reviewed version of the following article, which has been published in final form at http://onlinelibrary.wiley.com/doi/10.1111/bph.14075/abstract. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. Funder: Biotechnology and Biological Sciences Research Council (GrantNumber(s): BB/M000176/1). Running title: Pharmacology of the calcitonin/CGRP family appears under main title in pdf format.",
year = "2017",
month = "11",
day = "28",
doi = "10.1111/bph.14075",
language = "English",
volume = "In press",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",

}

Update on the pharmacology of calcitonin/CGRP family of peptides : IUPHAR Review 25. / Hay, Debbie L.; Garelja, Michael L.; Poyner, David R; Walker, Christopher S.

In: British Journal of Pharmacology, Vol. In press, 28.11.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Update on the pharmacology of calcitonin/CGRP family of peptides

T2 - British Journal of Pharmacology

AU - Hay, Debbie L.

AU - Garelja, Michael L.

AU - Poyner, David R

AU - Walker, Christopher S.

N1 - © 2017 The British Pharmacological Society and John Wiley & Sons, Inc. This is the peer reviewed version of the following article, which has been published in final form at http://onlinelibrary.wiley.com/doi/10.1111/bph.14075/abstract. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. Funder: Biotechnology and Biological Sciences Research Council (GrantNumber(s): BB/M000176/1). Running title: Pharmacology of the calcitonin/CGRP family appears under main title in pdf format.

PY - 2017/11/28

Y1 - 2017/11/28

N2 - The calcitonin/calcitonin gene-related peptide (CGRP) family of peptides includes calcitonin, α and β CGRP, amylin, adrenomedullin (AM) and adrenomedullin 2/intermedin (AM2/IMD). Their receptors consist of one of two G protein-coupled receptors (GPCRs), the calcitonin receptor (CTR) or the calcitonin receptor-like receptor (CLR). Further diversity arises from heterodimerisation of these GPCRs with one of three receptor activity-modifying proteins (RAMPs). This gives the CGRP receptor (CLR/RAMP1), the AM1 and AM2 receptors (CLR/RAMP2 or RAMP3) and the AMY1, AMY2 and AMY3 receptors (CTR/RAMPs1-3 complexes, respectively). Apart from the CGRP receptor, there are only peptide antagonists widely available for these receptors and these have limited selectivity, thus defining the function of each receptor in vivo remains challenging. Further challenges arise from the probable co-expression of CTR with the CTR/RAMP complexes and species-dependent splice variants of the CTR (CT(a) and CT(b)). Furthermore, the AMY1(a) receptor is activated equally well by both amylin and CGRP and the preferred receptor for AM2/IMD has been unclear. However, there are clear therapeutic rationales for developing agents against the various receptors for these peptides. For example many agents targeting the CGRP system are in clinical trials and pramlintide, an amylin analogue, is an approved therapy for insulin-requiring diabetes. This review provides an update on the pharmacology of the calcitonin family of peptides by members of the corresponding subcommittee of the International Union of Basic and Clinical Pharmacology and colleagues.

AB - The calcitonin/calcitonin gene-related peptide (CGRP) family of peptides includes calcitonin, α and β CGRP, amylin, adrenomedullin (AM) and adrenomedullin 2/intermedin (AM2/IMD). Their receptors consist of one of two G protein-coupled receptors (GPCRs), the calcitonin receptor (CTR) or the calcitonin receptor-like receptor (CLR). Further diversity arises from heterodimerisation of these GPCRs with one of three receptor activity-modifying proteins (RAMPs). This gives the CGRP receptor (CLR/RAMP1), the AM1 and AM2 receptors (CLR/RAMP2 or RAMP3) and the AMY1, AMY2 and AMY3 receptors (CTR/RAMPs1-3 complexes, respectively). Apart from the CGRP receptor, there are only peptide antagonists widely available for these receptors and these have limited selectivity, thus defining the function of each receptor in vivo remains challenging. Further challenges arise from the probable co-expression of CTR with the CTR/RAMP complexes and species-dependent splice variants of the CTR (CT(a) and CT(b)). Furthermore, the AMY1(a) receptor is activated equally well by both amylin and CGRP and the preferred receptor for AM2/IMD has been unclear. However, there are clear therapeutic rationales for developing agents against the various receptors for these peptides. For example many agents targeting the CGRP system are in clinical trials and pramlintide, an amylin analogue, is an approved therapy for insulin-requiring diabetes. This review provides an update on the pharmacology of the calcitonin family of peptides by members of the corresponding subcommittee of the International Union of Basic and Clinical Pharmacology and colleagues.

KW - Adrenomedullin

KW - amylin

KW - calcitonin

KW - CGRP

KW - migraine

KW - diabetes

UR - http://onlinelibrary.wiley.com/doi/10.1111/bph.14075/abstract

U2 - 10.1111/bph.14075

DO - 10.1111/bph.14075

M3 - Article

VL - In press

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

ER -